Prosecution Insights
Last updated: November 18, 2026
Application No. 18/358,958

APPLICATION OF GANCICLOVIR IN PREPAPRATION OF MEDICINE FOR TREATING ALLERGIC RHINITIS

Non-Final OA §102§112
Filed
Jul 26, 2023
Priority
Feb 16, 2023 — CN 2023101293738 +1 more
Examiner
COPPINS, JANET L
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
OA Round
2 (Non-Final)
72%
Grant Probability
Favorable
2-3
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
677 granted / 934 resolved
+12.5% vs TC avg
Strong +26% interview lift
Without
With
+26.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
50 currently pending
Career history
1011
Total Applications
across all art units

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-9, are pending in this application. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 4-8, are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Comprise(s), e.g. claims 2, line 2, is an open-ended term implying other allergic symptoms not cited in the claim are claimed. Hence, the claims 2, 4-8, are indefinite. Replacing comprise(s) with “is”, in every occurrence will obviate the rejection. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-9, are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chen, CN 116585321 A (filed date 2/21/23), which teaches a composition comprising ganciclovir for treating allergic rhinitis, wherein the subject has rhinocleisis, rhinocnesmus, sneezing or rhinorrhea (fig. 2). The prior art teaches administering the composition alone or in combination with another allergic rhinitis medicine (summary of invention). The administration can be oral, in form of capsules, granules, tablets, pulvis, etc. or by nasal spray. The administration is for 7-14 days followed by another allergic rhinitis medicine for 7-14 days (summary of invention). The other medicine can be a nasal spray hormone, and an oral antihistamine selected from the list in summary of invention. The dose is 250-500 mg, twice daily for a 14-year old and above, while it is 125-250 mg, twice daily for under 14 years old. See also the entire document, particularly the abstract, summary of invention, treatment examples, and figure 2. IDS No IDS was filed in this application. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." See the MPEP 2000 and 37 CFR 1.97, 1.98. The references and English translations of all foreign documents must be submitted. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, whose telephone number is (571) 272-0709. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Andy Kosar, can be reached on (571) 272-0913. The fax phone number for this Group is (571) 273-8300. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600. /TAOFIQ A SOLOLA/Primary Examiner, Art Unit 1625 October 28, 2025
Read full office action

Prosecution Timeline

Jul 26, 2023
Application Filed
Nov 06, 2025
Non-Final Rejection mailed — §102, §112
Feb 05, 2026
Response Filed
Nov 17, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12728129
MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
4y 8m to grant Granted Sep 08, 2026
Patent 12702150
Methods and Compositions for Slowing an Aging Process in a Human or an Animal
4y 11m to grant Granted Aug 11, 2026
Patent 12673955
NEW CRYSTAL FORM OF P-TOLUENESULFONATE SALT OF DIAZABICYCLIC COMPOUND AND PREPARATION METHOD THEREFOR
3y 4m to grant Granted Jul 07, 2026
Patent 12636297
BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
4y 5m to grant Granted May 26, 2026
Patent 12611405
AGENT THAT INCREASES THE EXPRESSION OF THE BCL2-ASSOCIATED AGONIST OF CELL DEATH FOR THE TREATMENT OF CANCER
6y 7m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
72%
Grant Probability
99%
With Interview (+26.2%)
Moderate
PTA Risk
Based on 934 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month